Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018


SUMMIT, N.J. & CAMBRIDGE, Mass.-- --Dec 1, 2018--Celgene Corporation and Acceleron Pharma Inc. today announced results from a pivotal, phase 3 trial evaluating the safety and efficacy of luspatercept for the treatment of adults with beta-thalassemia-associated anemia who require regular red blood cell transfusions. The data were presented by Maria Domenica Cappellini, M.D. in an oral session of the 60 th American Society of Hematology Annual Meeting and Exposition in San Diego, CA .



from Biotech News